APO Research
Talk to an analyst

APO RESEARCH · REPORT

VMAT2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global VMAT2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025194 pages

Choose your research edition.

Industry ResearchVMAT2 Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal VMAT2 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal VMAT2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VMAT2 Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal VMAT2 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global VMAT2 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VMAT2 Inhibitor include Teva, Sandoz, Mylan, Zydus, Sun Pharmaceutical, Neurocrine Biosciences, Lupin, Hetero and Dr. Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VMAT2 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VMAT2 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VMAT2 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VMAT2 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

VMAT2 Inhibitor Segment by Company

Teva

Sandoz

Mylan

Zydus

Sun Pharmaceutical

Neurocrine Biosciences

Lupin

Hetero

Dr. Reddy's Laboratories

Chartwell Pharmaceuticals

Bionpharma

Bausch Health

Apotex

Actavis Laboratories

VMAT2 Inhibitor Segment by Type

Deutetrabenazine

Tetrabenazine

Valbenazine

VMAT2 Inhibitor Segment by Application

Chorea Caused by Huntington's Disease

Tardive Dyskinesia

Other

VMAT2 Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VMAT2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VMAT2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VMAT2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VMAT2 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of VMAT2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of VMAT2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of VMAT2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. VMAT2 Inhibitor Industry Trends Table 2. VMAT2 Inhibitor Industry Drivers Table 3. VMAT2 Inhibitor Industry Opportunities and Challenges Table 4. VMAT2 Inhibitor Industry Restraints Table 5. Global VMAT2 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global VMAT2 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global VMAT2 Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global VMAT2 Inhibitor Sales Market Share by Manufacturers Table 9. Global VMAT2 Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global VMAT2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global VMAT2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global VMAT2 Inhibitor Manufacturers, Product Type & Application Table 13. Global VMAT2 Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global VMAT2 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Deutetrabenazine Table 17. Major Manufacturers of Tetrabenazine Table 18. Major Manufacturers of Valbenazine Table 19. Global VMAT2 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global VMAT2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. Global VMAT2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 22. Global VMAT2 Inhibitor Sales Market Share by Type (2021-2026) Table 23. Global VMAT2 Inhibitor Sales Market Share by Type (2027-2032) Table 24. Global VMAT2 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global VMAT2 Inhibitor Revenue by Type (2021-2026) & (K Units) Table 26. Global VMAT2 Inhibitor Revenue by Type (2027-2032) & (K Units) Table 27. Global VMAT2 Inhibitor Revenue Market Share by Type (2021-2026) Table 28. Global VMAT2 Inhibitor Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Chorea Caused by Huntington's Disease Table 30. Major Manufacturers of Tardive Dyskinesia Table 31. Major Manufacturers of Other Table 32. Global VMAT2 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global VMAT2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 34. Global VMAT2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 35. Global VMAT2 Inhibitor Sales Market Share by Application (2021-2026) Table 36. Global VMAT2 Inhibitor Sales Market Share by Application (2027-2032) Table 37. Global VMAT2 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global VMAT2 Inhibitor Revenue by Application (2021-2026) & (K Units) Table 39. Global VMAT2 Inhibitor Revenue by Application (2027-2032) & (K Units) Table 40. Global VMAT2 Inhibitor Revenue Market Share by Application (2021-2026) Table 41. Global VMAT2 Inhibitor Revenue Market Share by Application (2027-2032) Table 42. Global VMAT2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global VMAT2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 44. Global VMAT2 Inhibitor Sales Market Share by Region (2021-2026) Table 45. Global VMAT2 Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global VMAT2 Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 47. North America VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America VMAT2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 49. North America VMAT2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 50. Europe VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe VMAT2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 52. Europe VMAT2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific VMAT2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific VMAT2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa VMAT2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa VMAT2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 59. Global VMAT2 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global VMAT2 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 61. Global VMAT2 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 62. Global VMAT2 Inhibitor Revenue Market Share by Region (2021-2026) Table 63. Global VMAT2 Inhibitor Revenue Market Share by Region (2027-2032) Table 64. Teva Company Information Table 65. Teva Business Overview Table 66. Teva VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva VMAT2 Inhibitor Product Portfolio Table 68. Teva Recent Development Table 69. Sandoz Company Information Table 70. Sandoz Business Overview Table 71. Sandoz VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sandoz VMAT2 Inhibitor Product Portfolio Table 73. Sandoz Recent Development Table 74. Mylan Company Information Table 75. Mylan Business Overview Table 76. Mylan VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Mylan VMAT2 Inhibitor Product Portfolio Table 78. Mylan Recent Development Table 79. Zydus Company Information Table 80. Zydus Business Overview Table 81. Zydus VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Zydus VMAT2 Inhibitor Product Portfolio Table 83. Zydus Recent Development Table 84. Sun Pharmaceutical Company Information Table 85. Sun Pharmaceutical Business Overview Table 86. Sun Pharmaceutical VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sun Pharmaceutical VMAT2 Inhibitor Product Portfolio Table 88. Sun Pharmaceutical Recent Development Table 89. Neurocrine Biosciences Company Information Table 90. Neurocrine Biosciences Business Overview Table 91. Neurocrine Biosciences VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Neurocrine Biosciences VMAT2 Inhibitor Product Portfolio Table 93. Neurocrine Biosciences Recent Development Table 94. Lupin Company Information Table 95. Lupin Business Overview Table 96. Lupin VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Lupin VMAT2 Inhibitor Product Portfolio Table 98. Lupin Recent Development Table 99. Hetero Company Information Table 100. Hetero Business Overview Table 101. Hetero VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Hetero VMAT2 Inhibitor Product Portfolio Table 103. Hetero Recent Development Table 104. Dr. Reddy's Laboratories Company Information Table 105. Dr. Reddy's Laboratories Business Overview Table 106. Dr. Reddy's Laboratories VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Dr. Reddy's Laboratories VMAT2 Inhibitor Product Portfolio Table 108. Dr. Reddy's Laboratories Recent Development Table 109. Chartwell Pharmaceuticals Company Information Table 110. Chartwell Pharmaceuticals Business Overview Table 111. Chartwell Pharmaceuticals VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Chartwell Pharmaceuticals VMAT2 Inhibitor Product Portfolio Table 113. Chartwell Pharmaceuticals Recent Development Table 114. Bionpharma Company Information Table 115. Bionpharma Business Overview Table 116. Bionpharma VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bionpharma VMAT2 Inhibitor Product Portfolio Table 118. Bionpharma Recent Development Table 119. Bausch Health Company Information Table 120. Bausch Health Business Overview Table 121. Bausch Health VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Bausch Health VMAT2 Inhibitor Product Portfolio Table 123. Bausch Health Recent Development Table 124. Apotex Company Information Table 125. Apotex Business Overview Table 126. Apotex VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Apotex VMAT2 Inhibitor Product Portfolio Table 128. Apotex Recent Development Table 129. Actavis Laboratories Company Information Table 130. Actavis Laboratories Business Overview Table 131. Actavis Laboratories VMAT2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Actavis Laboratories VMAT2 Inhibitor Product Portfolio Table 133. Actavis Laboratories Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. VMAT2 Inhibitor Distributors List Table 137. VMAT2 Inhibitor Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. VMAT2 Inhibitor Product Image Figure 2. Global VMAT2 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VMAT2 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global VMAT2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global VMAT2 Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 VMAT2 Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Deutetrabenazine Image Figure 9. Tetrabenazine Image Figure 10. Valbenazine Image Figure 11. Global VMAT2 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global VMAT2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global VMAT2 Inhibitor Sales Market Share by Type (2021-2032) Figure 14. Global VMAT2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global VMAT2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global VMAT2 Inhibitor Revenue Market Share by Type (2021-2032) Figure 17. Chorea Caused by Huntington's Disease Image Figure 18. Tardive Dyskinesia Image Figure 19. Other Image Figure 20. Global VMAT2 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global VMAT2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global VMAT2 Inhibitor Sales Market Share by Application (2021-2032) Figure 23. Global VMAT2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global VMAT2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global VMAT2 Inhibitor Revenue Market Share by Application (2021-2032) Figure 26. North America VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America VMAT2 Inhibitor Sales Market Share by Country (2021-2032) Figure 28. U.S. VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe VMAT2 Inhibitor Sales Market Share by Country (2021-2032) Figure 33. Germany VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific VMAT2 Inhibitor Sales Market Share by Country (2021-2032) Figure 40. China VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa VMAT2 Inhibitor Sales Market Share by Country (2021-2032) Figure 48. Brazil VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile VMAT2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global VMAT2 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global VMAT2 Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America VMAT2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 59. North America VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe VMAT2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 61. Europe VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific VMAT2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa VMAT2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. VMAT2 Inhibitor Value Chain Figure 67. Manufacturing Cost Structure Figure 68. VMAT2 Inhibitor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Deutetrabenazine
  • Tetrabenazine
  • Valbenazine
Applications
  • Chorea Caused by Huntington's Disease
  • Tardive Dyskinesia
  • Other
Companies covered
  • Teva
  • Sandoz
  • Mylan
  • Zydus
  • Sun Pharmaceutical
  • Neurocrine Biosciences
  • Lupin
  • Hetero
  • Dr. Reddy's Laboratories
  • Chartwell Pharmaceuticals
  • Bionpharma
  • Bausch Health
  • Apotex
  • Actavis Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global VMAT2 Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global VMAT2 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global VMAT2 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global VMAT2 Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global VMAT2 Inhibitor Market Dynamics
  1. 2.1 VMAT2 Inhibitor Industry Trends
  2. 2.2 VMAT2 Inhibitor Industry Drivers
  3. 2.3 VMAT2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 VMAT2 Inhibitor Industry Restraints
3 VMAT2 Inhibitor Market by Manufacturers
  1. 3.1 Global VMAT2 Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global VMAT2 Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global VMAT2 Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global VMAT2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global VMAT2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global VMAT2 Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global VMAT2 Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global VMAT2 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 VMAT2 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 VMAT2 Inhibitor Tier 1, Tier 2, and Tier 3
4 VMAT2 Inhibitor Market by Type
  1. 4.1 VMAT2 Inhibitor Type Introduction
  2. 4.1.1 Deutetrabenazine
  3. 4.1.2 Tetrabenazine
  4. 4.1.3 Valbenazine
  5. 4.2 Global VMAT2 Inhibitor Sales by Type
  6. 4.2.1 Global VMAT2 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global VMAT2 Inhibitor Sales by Type (2021-2032)
  8. 4.2.3 Global VMAT2 Inhibitor Sales Market Share by Type (2021-2032)
  9. 4.3 Global VMAT2 Inhibitor Revenue by Type
  10. 4.3.1 Global VMAT2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global VMAT2 Inhibitor Revenue by Type (2021-2032)
  12. 4.3.3 Global VMAT2 Inhibitor Revenue Market Share by Type (2021-2032)
5 VMAT2 Inhibitor Market by Application
  1. 5.1 VMAT2 Inhibitor Application Introduction
  2. 5.1.1 Chorea Caused by Huntington's Disease
  3. 5.1.2 Tardive Dyskinesia
  4. 5.1.3 Other
  5. 5.2 Global VMAT2 Inhibitor Sales by Application
  6. 5.2.1 Global VMAT2 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VMAT2 Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global VMAT2 Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global VMAT2 Inhibitor Revenue by Application
  10. 5.3.1 Global VMAT2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VMAT2 Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global VMAT2 Inhibitor Revenue Market Share by Application (2021-2032)
6 Global VMAT2 Inhibitor Sales by Region
  1. 6.1 Global VMAT2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VMAT2 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global VMAT2 Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global VMAT2 Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America VMAT2 Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe VMAT2 Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific VMAT2 Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa VMAT2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa VMAT2 Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global VMAT2 Inhibitor Revenue by Region
  1. 7.1 Global VMAT2 Inhibitor Revenue by Region
  2. 7.1.1 Global VMAT2 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global VMAT2 Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global VMAT2 Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global VMAT2 Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America VMAT2 Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe VMAT2 Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific VMAT2 Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa VMAT2 Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa VMAT2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva VMAT2 Inhibitor Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz VMAT2 Inhibitor Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan VMAT2 Inhibitor Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Zydus
  20. 8.4.1 Zydus Company Information
  21. 8.4.2 Zydus Business Overview
  22. 8.4.3 Zydus VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zydus VMAT2 Inhibitor Product Portfolio
  24. 8.4.5 Zydus Recent Developments
  25. 8.5 Sun Pharmaceutical
  26. 8.5.1 Sun Pharmaceutical Company Information
  27. 8.5.2 Sun Pharmaceutical Business Overview
  28. 8.5.3 Sun Pharmaceutical VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharmaceutical VMAT2 Inhibitor Product Portfolio
  30. 8.5.5 Sun Pharmaceutical Recent Developments
  31. 8.6 Neurocrine Biosciences
  32. 8.6.1 Neurocrine Biosciences Company Information
  33. 8.6.2 Neurocrine Biosciences Business Overview
  34. 8.6.3 Neurocrine Biosciences VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Neurocrine Biosciences VMAT2 Inhibitor Product Portfolio
  36. 8.6.5 Neurocrine Biosciences Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lupin VMAT2 Inhibitor Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Hetero
  44. 8.8.1 Hetero Company Information
  45. 8.8.2 Hetero Business Overview
  46. 8.8.3 Hetero VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hetero VMAT2 Inhibitor Product Portfolio
  48. 8.8.5 Hetero Recent Developments
  49. 8.9 Dr. Reddy's Laboratories
  50. 8.9.1 Dr. Reddy's Laboratories Company Information
  51. 8.9.2 Dr. Reddy's Laboratories Business Overview
  52. 8.9.3 Dr. Reddy's Laboratories VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dr. Reddy's Laboratories VMAT2 Inhibitor Product Portfolio
  54. 8.9.5 Dr. Reddy's Laboratories Recent Developments
  55. 8.10 Chartwell Pharmaceuticals
  56. 8.10.1 Chartwell Pharmaceuticals Company Information
  57. 8.10.2 Chartwell Pharmaceuticals Business Overview
  58. 8.10.3 Chartwell Pharmaceuticals VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chartwell Pharmaceuticals VMAT2 Inhibitor Product Portfolio
  60. 8.10.5 Chartwell Pharmaceuticals Recent Developments
  61. 8.11 Bionpharma
  62. 8.11.1 Bionpharma Company Information
  63. 8.11.2 Bionpharma Business Overview
  64. 8.11.3 Bionpharma VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bionpharma VMAT2 Inhibitor Product Portfolio
  66. 8.11.5 Bionpharma Recent Developments
  67. 8.12 Bausch Health
  68. 8.12.1 Bausch Health Company Information
  69. 8.12.2 Bausch Health Business Overview
  70. 8.12.3 Bausch Health VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bausch Health VMAT2 Inhibitor Product Portfolio
  72. 8.12.5 Bausch Health Recent Developments
  73. 8.13 Apotex
  74. 8.13.1 Apotex Company Information
  75. 8.13.2 Apotex Business Overview
  76. 8.13.3 Apotex VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Apotex VMAT2 Inhibitor Product Portfolio
  78. 8.13.5 Apotex Recent Developments
  79. 8.14 Actavis Laboratories
  80. 8.14.1 Actavis Laboratories Company Information
  81. 8.14.2 Actavis Laboratories Business Overview
  82. 8.14.3 Actavis Laboratories VMAT2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Actavis Laboratories VMAT2 Inhibitor Product Portfolio
  84. 8.14.5 Actavis Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VMAT2 Inhibitor Value Chain Analysis
  2. 9.1.1 VMAT2 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VMAT2 Inhibitor Production Mode & Process
  6. 9.2 VMAT2 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VMAT2 Inhibitor Distributors
  9. 9.2.3 VMAT2 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst